Clinical Trials Arena on MSN3d
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trial
Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...
FierceBiotech25d
Takeda fronts $46M for 2nd small molecule collab with BridGene
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...